IntroductionThe first recorded outbreak of severe acute respiratory syndrome (SARS) in late February 2003 has led to thousands of infected patients and hundreds of deaths. The etiologic agent of the syndrome, a novel coronavirus termed SARS-associated coronavirus (SARS-CoV), has since been identified and isolated, 1-4 and its genome sequenced. 5,6 SARS is characterized by high fever, rigor, headache, nonproductive cough, or dyspnea and may progress to generalized, interstitial infiltrates in the lung, requiring intubation and mechanical ventilation. 1,2,7-9 A common observation in patients with SARS is pronounced lymphopenia. 1,10,11 A notable drop in CD4 ϩ and CD8 ϩ T lymphocyte counts occurs early in the course of the disease and is associated with adverse outcomes. 12 To date, studies on SARS have generally been retrospective or limited to the description of initial clinical, hematologic, radiologic, and microbiologic findings. Further studies to evaluate the mechanisms of these manifestations may help us to better understand this disease.Evidence suggests that CD8 ϩ cytotoxic T lymphocytes (CTLs) play a pivotal role in both virus elimination and induction of immunopathology in respiratory syncytial virus (RSV) infection, following recognition of epitopes presented on target cells in the context of major histocompatibility complex (MHC) class I. [13][14][15][16][17] Similarly, CTLs may participate in the clearance of virus in recovered SARS patients but also contribute to immunopathology in early stages of the disease; the molecular mechanisms underlying these CD8 ϩ CTL-mediated effects remain poorly defined. HLA-A2 is the most common HLA-A allele in Asian populations, particularly in the Chinese, with an estimated frequency of more than 50%. 18 As SARS affected many parts of Asia, and a reservoir of infection may persist in these regions, the identification of HLA-A*0201-restricted CTL epitopes of SARS-CoV is an important contribution to future studies concerning the role of CTLs in SARS-CoV pathogenesis and protection in at-risk populations.Here we have studied a panel of SARS-CoV spike protein (SARS/S)-derived peptides to identify those with binding motifs for HLA-A*0201 molecules. We evaluated the ability of HLA-A*0201 binding peptides to provoke in vivo-and in vitro-specific CTL responses in HLA-A2.1/K b transgenic (Tg) mice and peripheral blood lymphocyte (PBL) preparations from MHC-matched healthy donors, using dendritic cells (DCs) prepulsed with the peptides. Our findings show that anti-SARS-CoV CTLs generated from Tg mice and PBLs of healthy donors can elicit an antigenspecific, HLA-A2.1-restricted response, effectively killing peptidepulsed T2 cells or HLA-A2.1 ϩ tumor cell lines endogenously For personal use only. on May 10, 2018. by guest www.bloodjournal.org From expressing S protein. To the best of our knowledge, our study is the first successful prospective identification of a novel HLA-A*0201-restricted CD8 ϩ T-cell epitope from the SARS-CoV spike protein.
Materials and methods
PeptidesTo ide...